CLEVELAND, February 23, 2024 — The National Cord Blood Network (NCBN) proudly announces its official launch, signaling a new era of advances and collaboration in cord blood transplantation. The NCBN aims to increase accessibility to life-saving cord blood transplantation for patients with hematologic malignancies in US Transplant Centers as well as optimize cord blood transplant practices. [Read more…]
RESILIÉLLE COSMETICS LLC Unveils Exosome Results of First-Ever 100-Person Trial on Age Zero Exosome Cosmetic Serum Applied Topically Post Microneedling
Eight Medical Spas Participate in Nationwide Pioneering Study
Rochester NY, February 13, 2024 – RESILIÉLLETM Cosmetics LLC, a leader in innovative skincare solutions, proudly announces the successful completion of the world’s first 100-person microneedling-plus-exosome trial, conducted at eight renowned medspas across the country. The clinicians participated in the trial in order to analyze what is the most effective amount of RESILIÉLLE Age Zero ExosomeTM topical serum to be applied after facial microneedling. [Read more…]
Custom iPSC Engineering Services – 4 Reasons to Choose Applied StemCell
Applied StemCell Inc. (ASC) is a gene-editing company that offers an optimized series of tools for basic research study, drug discovery, bio-processing, bio-production and preclinical applications. Currently, the company is focused on the following areas:
- Cell line generation for bio-production and bioassays
- Patient-relevant cell models for personalized medicine
- Physiologically predictive animal and cellular models of human disease
Applied StemCell uses its TARGATT™ technology to specifically insert a gene-of-interest at a well-characterized, transcriptionally active locus in the genome with guaranteed transgene expression. This site-specific knock-in technology was first established in mouse models, and ASC has successfully applied it to human cell lines.
ASC has leveraged this technology across various projects that combine the complementary CRISPR/Cas9 technology and TARGATT™ for highly specified transgene expression. [Read more…]
AVANT BIO Emerges as a Leading Equity Firm in Life Sciences, Tech Bio, and HealthTech
NEW YORK — AVANT BIO LLC, a pioneering early stage and growth equity firm, announces its official launch, positioning itself at the forefront of today’s transformative landscape in life sciences, tech bio, and healthtech industries. The Firm’s investments align with the convergence of groundbreaking technologies and an enhanced understanding of biology, creating a powerful synergy poised for breakthrough advancements in the future. [Read more…]
The Present and Future Trajectory of the Cord Blood & Tissue Banking Market
Umbilical cord blood (UCB) has been an accepted source of hematopoietic stem cells (HSC) for transplantation for more than 30 years. Umbilical cord-derived stem cells are the youngest cells available for transfusion and yet their uptake lags behind bone marrow and peripheral blood-derived HSCs. Decreased engraftment rates and the low cell dose available for transplantation are limitations that are preventing umbilical cord blood-derived cells from reaching their full potential. While a handful of companies are now developing cord blood and tissue-derived cell therapeutics, it will likely take several years for these products to reach commercialization. [Read more…]
- « Previous Page
- 1
- …
- 111
- 112
- 113
- 114
- 115
- …
- 339
- Next Page »